These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 2115096)

  • 41. Practical Guide to Cost-effectiveness Analysis.
    Brooke BS; Kaji AH; Itani KMF
    JAMA Surg; 2020 Mar; 155(3):250-251. PubMed ID: 31995143
    [No Abstract]   [Full Text] [Related]  

  • 42. Cost-Effectiveness Analysis Expands its Reach Worldwide.
    Greenberg D; Neumann PJ
    Value Health Reg Issues; 2016 Sep; 10():101-102. PubMed ID: 27881271
    [No Abstract]   [Full Text] [Related]  

  • 43. The Next Chapter in Cost-effectiveness Analysis.
    Roberts MS
    JAMA; 2016 Sep; 316(10):1049-50. PubMed ID: 27623460
    [No Abstract]   [Full Text] [Related]  

  • 44. The conundrum of cost-effectiveness.
    Prasad V
    Cleve Clin J Med; 2012 Sep; 79(9):610-1. PubMed ID: 22949341
    [No Abstract]   [Full Text] [Related]  

  • 45. The solid angle of a plane triangle.
    van Oosterom A; Strackee J
    IEEE Trans Biomed Eng; 1983 Feb; 30(2):125-6. PubMed ID: 6832789
    [No Abstract]   [Full Text] [Related]  

  • 46. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.
    Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
    Value Health; 2013; 16(2):e1-5. PubMed ID: 23538200
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
    Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
    Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How to estimate productivity costs in economic evaluations.
    Krol M; Brouwer W
    Pharmacoeconomics; 2014 Apr; 32(4):335-44. PubMed ID: 24504850
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health economic evaluation: important principles and methodology.
    Rudmik L; Drummond M
    Laryngoscope; 2013 Jun; 123(6):1341-7. PubMed ID: 23483522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting.
    Petrou S; Gray A
    BMJ; 2011 Apr; 342():d1766. PubMed ID: 21482590
    [No Abstract]   [Full Text] [Related]  

  • 52. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis.
    Stinnett AA; Mullahy J
    Med Decis Making; 1998; 18(2 Suppl):S68-80. PubMed ID: 9566468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force.
    Husereau D; Drummond M; Augustovski F; de Bekker-Grob E; Briggs AH; Carswell C; Caulley L; Chaiyakunapruk N; Greenberg D; Loder E; Mauskopf J; Mullins CD; Petrou S; Pwu RF; Staniszewska S
    Value Health; 2022 Jan; 25(1):10-31. PubMed ID: 35031088
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The augmented representation of the cost-effectiveness acceptability curve for economic evaluation of health technology.
    Araki D; Kamae I
    Kobe J Med Sci; 2015 Mar; 61(1):E9-18. PubMed ID: 25868612
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials.
    Faria R; Gomes M; Epstein D; White IR
    Pharmacoeconomics; 2014 Dec; 32(12):1157-70. PubMed ID: 25069632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness acceptability curves revisited.
    Al MJ
    Pharmacoeconomics; 2013 Feb; 31(2):93-100. PubMed ID: 23329426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of pessary therapy versus surgery for symptomatic pelvic organ prolapse: an economic evaluation alongside a randomised non-inferiority controlled trial.
    Ben ÂJ; van der Vaart LR; E Bosmans J; Roovers JWR; Lagro-Janssen ALM; van der Vaart CH; Vollebregt A;
    BMJ Open; 2024 May; 14(5):e075016. PubMed ID: 38692718
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two-year follow-up of a clustered randomised controlled trial of a multicomponent general practice intervention for people at risk of poor health outcomes.
    Reed RL; Roeger L; Kaambwa B
    BMC Health Serv Res; 2024 Apr; 24(1):488. PubMed ID: 38641587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of septoplasty compared to medical management in adults with obstruction associated with a deviated nasal septum: the NAIROS RCT.
    Carrie S; Fouweather T; Homer T; O'Hara J; Rousseau N; Rooshenas L; Bray A; Stocken DD; Ternent L; Rennie K; Clark E; Waugh N; Steel AJ; Dooley J; Drinnan M; Hamilton D; Lloyd K; Oluboyede Y; Wilson C; Gardiner Q; Kara N; Khwaja S; Leong SC; Maini S; Morrison J; Nix P; Wilson JA; Teare MD
    Health Technol Assess; 2024 Mar; 28(10):1-213. PubMed ID: 38477237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tonsillectomy compared with conservative management in patients over 16 years with recurrent sore throat: the NATTINA RCT and economic evaluation.
    Wilson JA; Fouweather T; Stocken DD; Homer T; Haighton C; Rousseau N; O'Hara J; Vale L; Wilson R; Carnell S; Wilkes S; Morrison J; Ah-See K; Carrie S; Hopkins C; Howe N; Hussain M; Lindley L; MacKenzie K; McSweeney L; Mehanna H; Raine C; Whelan RS; Sullivan F; von Wilamowitz-Moellendorff A; Teare D
    Health Technol Assess; 2023 Dec; 27(31):1-195. PubMed ID: 38204203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.